Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough
PLOS One · 2025
DOI: 10.1371/journal.pone.0333526 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Nattapon Riengvirodkij und 6 weiteren Autor:innen. Beteiligte Einrichtung: Prasu Arthorn Veterinary Teaching Hospital, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Cough, Dog Diseases, Exercise Tolerance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pharmalink International Ltd. Central, Hong Kong.
Abstract (Originalsprache)
Pulmonary hypertension (PH) in dogs, characterized by abnormally high blood pressure in the pulmonary arteries, presents a management challenge, and adjunctive therapies for the standard treatment of sildenafil are needed. This study aimed to determine whether the nutraceutical Perna canaliculus oil (PCSO-524), a marine lipid extract with anti-inflammatory properties, provides additional clinical benefits to dogs with PH. In a prospective, randomized, placebo-controlled trial, seventeen client-owned dogs diagnosed with PH were assigned to receive either PCSO-524 or a placebo as an add-on to their sildenafil-based therapy for 70 days. Key outcomes were evaluated using owner-assessed clinical scores for exercise tolerance and coughing, alongside echocardiographic measurements. The PCSO-524 group demonstrated a statistically significant improvement in exercise tolerance scores by day 70 (P = 0.009). This group also showed a greater reduction in coughing scores compared to the placebo group between day 35 and day 70 (P = 0.03). While the tricuspid regurgitation pressure gradient (TRPG), an estimate of pulmonary pressure, decreased significantly over time in all dogs (P = 0.001), no significant difference was found between the groups for this specific measure. These results indicate that PCSO-524 can serve as a beneficial adjunctive therapy for improving important clinical signs, such as exercise tolerance and coughing, in dogs with PH. This suggests it may be a valuable addition to standard management for enhancing quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Prasu Arthorn Veterinary Teaching Hospital, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
- Department of Clinical Sciences and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
- Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
- College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Australia.
ORCID-Profile: Walasinee Sakcamduang
Förderung
- Pharmalink International Ltd. Central, Hong Kong
Zitieren
APA
Riengvirodkij, N., Taechikantaphat, M., Ampapol, P., Kovorakul, T., Intaranat, S., Costa, N., & Sakcamduang, W. (2025). Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough. PLOS One. https://doi.org/10.1371/journal.pone.0333526
Vancouver
Riengvirodkij N, Taechikantaphat M, Ampapol P, Kovorakul T, Intaranat S, Costa N, et al. Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough. PLOS One. 2025. doi:10.1371/journal.pone.0333526
BibTeX
@article{Riengvirodkij2025,
author = {Riengvirodkij, Nattapon and Taechikantaphat, Mookmanee and Ampapol, Pichayut and Kovorakul, Theethach and Intaranat, Sapon and Costa, Nick and Sakcamduang, Walasinee},
title = {Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333526}
}
EUVIMED